Jeremy Levin, Ovid CEO
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Ovid Therapeutics investors have most eyes on the Phase III trial for their lead drug for Angelman syndrome and whether some controversial Phase II findings …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
